A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.
about
Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?Translational Bioinformatics: Past, Present, and FutureSmall cell lung cancer (SCLC): no treatment advances in recent yearsLeveraging big data to transform target selection and drug discoveryOrigins, genetic landscape, and emerging therapies of small cell lung cancerVoltage-gated ion channels in cancer cell proliferationUpdate in Lung Cancer 2014Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in ZebrafishGenome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disordersCadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapiesPharmacogenomic approach to identify drug sensitivity in small-cell lung cancerSurveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal GenomicsPrioritizing therapeutics for lung cancer: an integrative meta-analysis of cancer gene signatures and chemogenomic dataA Semi-Supervised Approach for Refining Transcriptional Signatures of Drug Response and Repositioning PredictionsFrom Bench to Bedside: Attempt to Evaluate Repositioning of Drugs in the Treatment of Metastatic Small Cell Lung Cancer (SCLC)Integrative network modeling approaches to personalized cancer medicineA survey of current trends in computational drug repositioningPathway analysis for drug repositioning based on public database miningExploiting large-scale drug-protein interaction information for computational drug repurposing.Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational researchIDEA: Integrated Drug Expression Analysis-Integration of Gene Expression and Clinical Data for the Identification of Therapeutic Candidates.Molecular pathways and therapeutic targets in lung cancerSerotonergic system antagonists target breast tumor initiating cells and synergize with chemotherapy to shrink human breast tumor xenografts.Small cell lung cancer: where do we go from here?Recycling existing drugs for cancer therapy: delivering low cost cancer careReversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targetsEvolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders.A DRD1 polymorphism predisposes to lung cancer among those exposed to secondhand smoke during childhood.Genomic analysis of fibrolamellar hepatocellular carcinoma.In vitro screening for drug repositioning.DT-Web: a web-based application for drug-target interaction and drug combination prediction through domain-tuned network-based inference.A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles.A weighted and integrated drug-target interactome: drug repurposing for schizophrenia as a use case.Cancer Mortality in People Treated with Antidepressants before Cancer Diagnosis: A Population Based Cohort Study.Analysis of the expression of Kv10.1 potassium channel in patients with brain metastases and glioblastoma multiforme: impact on survival.Small cell lung cancer: will recent progress lead to improved outcomes?Identification of new drug candidates against Borrelia burgdorferi using high-throughput screening.Repurposing Cationic Amphiphilic Antihistamines for Cancer TreatmentTowards precision medicine-based therapies for glioblastoma: interrogating human disease genomics and mouse phenotypesExpression Profiling Identifies Bezafibrate as Potential Therapeutic Drug for Lung Adenocarcinoma.
P2860
Q26748741-A71331FF-3DAA-4589-AF21-1A21D1EEF613Q26766146-0FBF8A15-E993-4044-A62D-D78A2C769BB7Q26767020-B7A40550-15D0-42CF-A37F-4B10476F2D73Q26776403-27111946-8C83-4422-BD9E-B8E705E2329FQ26798218-F5AE821E-FFCA-4D7D-9CFF-031AA8D53589Q27010511-ADF2A1A7-3766-4CE9-A3A2-F45D5E2C76A5Q27027385-2737A832-D6BF-4652-A865-2E0BA3F00DA9Q27310913-8CFC8EF1-36AA-4A74-B31A-DCB61869EE4FQ28082561-3FE61F62-B435-4C9B-9E2A-0C6977E15637Q28237085-BC468C7E-9CDA-43F5-84C3-1A0BEDF6ED9BQ28542859-A8A76057-9616-4C8E-9622-BFABE6793F54Q28542977-E8DB8A2C-E9C8-44D7-8936-CFC25BAA3C0FQ28544631-0DDC4BF7-CC60-4AA8-8478-1B77901A8692Q28550159-661D1293-8401-4D41-B496-503A784D7E3AQ28552102-7BBF9040-1B30-4BFD-974C-7C30AD6AF9BBQ28602016-E78435C4-943D-4454-B547-0730580D4796Q28602324-48979F32-7EA5-4D70-BC80-CFAADD087B35Q28657698-3A4A415B-B924-4227-BF2B-BF1C9E039C90Q30582560-AECDACB6-9F61-4221-A1C9-C4DEF254F1EFQ30965534-2F864B66-C382-4F91-805B-595F67E38A09Q30990059-8F51F037-08CF-4E6E-B001-36DAC44A2474Q33688872-758ADCD7-F1D2-4192-9AE5-6229A3B72304Q33762032-59F62870-C19B-4B11-A47E-A1FB5CC2EC55Q33872327-D9F254AD-E80E-461A-86A4-E9645A57385AQ33893944-4C2FCBCC-0DD1-455E-89F3-691EDB2EB47FQ33903831-1D5A1E30-E8E6-49A2-87A7-3CC41BC9EBF2Q34608239-DE0342E7-7A1C-4E43-A2D1-1B76771F3D20Q34633132-0A473BA8-274E-46B8-A0B9-857EC9810645Q34673400-9EE2D609-9E99-46D6-93CC-7B8B094076D7Q35531225-8302A9E3-E497-4C69-9C17-82A45AFFBF81Q35655576-4B77ECD5-2B94-4733-A0B7-0CD983799EC8Q35670972-C6FCF3EA-186B-4625-A935-257225124D83Q35671408-F0F33A93-B827-4DF9-9503-4AD0948B2186Q35772646-CD3174E2-361C-4559-93EE-DFA5112C05ADQ35830894-4E396E2D-F800-4A7D-8D22-208DB202F277Q35836257-449CA892-C1B5-483B-A7A2-FD514C896C37Q35996715-679BC40A-0B4A-4ACD-B3F4-2C57E8998B56Q36059021-FD9F6AE4-24DE-4910-9587-A33795388819Q36111611-E26C6F0E-A323-4FEF-B962-2820259B30F5Q36214115-8A215C72-347B-44D8-A0F1-008FD08F9658
P2860
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A drug repositioning approach ...... d other neuroendocrine tumors.
@en
A drug repositioning approach ...... d other neuroendocrine tumors.
@nl
type
label
A drug repositioning approach ...... d other neuroendocrine tumors.
@en
A drug repositioning approach ...... d other neuroendocrine tumors.
@nl
prefLabel
A drug repositioning approach ...... d other neuroendocrine tumors.
@en
A drug repositioning approach ...... d other neuroendocrine tumors.
@nl
P2093
P2860
P50
P1433
P1476
A drug repositioning approach ...... nd other neuroendocrine tumors
@en
P2093
Alec Palmerton
Anne-Flore Zmoos
Joel T Dudley
Joel W Neal
Jonathan W Riess
Karolina Krasinska
Kim Q T Tran
Kwon S Park
Margaret Zhou
P2860
P304
P356
10.1158/2159-8290.CD-13-0183
P577
2013-09-26T00:00:00Z